Upregulation of selective cholesteryl ester uptake pathway in mice with deletion of low-density lipoprotein receptor function.
This study examines the effect of mutation of the low-density lipoprotein receptor (LDLR) on cholesterol metabolism, and especially lipoprotein-derived cholesteryl ester uptake, in murine ovarian granulosa cells. Although the tests were conducted on cells prepared by two different procedures, the results are similar. Deletion of LDLR function did not noticeably affect key enzymes of the steroidogenic pathway or affect progestin production and secretion in granulosa cells. No change was found in expression of LDL-related protein (LRP). These data suggested that cholesterol turnover in cells from the knockout animals is within normal limits and that the cells are not stressed to acquire more cholesterol. Both biochemical and morphological data indicate that unstimulated granulosa cells from LDLR-/- mice are nonetheless programmed to take in double the amount of lipoprotein-derived cholesteryl ester (via the selective cholesteryl ester uptake pathway) and to process (hydrolyze, re-esterify, or utilize) more than twofold the cholesteryl ester processed by cells from wildtype (LDLR+/+) animals. Bt2cAMP stimulation of the murine granulosa cells increases the mass of cholesteryl ester taken up by the selective pathway by an additional 38%. To determine to what extent this increase is related to high-density lipoprotein (HDL) scavenger receptor protein (SR-BI) or caveolin function, Western blots and immunohistochemical studies were performed under a variety of conditions. SR-BI levels are found to be low in unstimulated cells of both LDLR+/+ and LDLR-/- animals, but highly expressed (approximately 20-fold increase over basal levels) in stimulated (Bt2cAMP) cells of both animal models. Thus, the functional relationship between selective cholesteryl ester uptake and SR-BI receptor protein is not as tight as in previously reported studies, suggesting a requirement for other tissue factors. Caveolin expression did not change under any of the conditions tested and appears not to be functionally involved in this process.
Geriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, California 94304, USA.
S
S
Azhar
Y
Y
Luo
S
S
Medicherla
E
E
Reaven
D000818:Animals; D001692:Biological Transport / Q000187:drug effects / Q000502:physiology; D001896:Boron Compounds / Q000493:pharmacokinetics*; D003994:Bucladesine / Q000494:pharmacology; D018955:CD36 Antigens / Q000032:analysis / Q000235:genetics; D051242:Caveolin 1; D022461:Caveolins; D002478:Cells, Cultured; D002788:Cholesterol Esters / Q000493:pharmacokinetics*; D008076:Cholesterol, HDL / Q000493:pharmacokinetics*; D005260:Female; D005455:Fluorescent Antibody Technique; D015870:Gene Expression / Q000502:physiology; D006107:Granulosa Cells / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes; D008074:Lipoproteins / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000032:analysis / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015345:Oligonucleotide Probes; D012333:RNA, Messenger / Q000032:analysis; D011971:Receptors, Immunologic; D011973:Receptors, LDL / Q000235:genetics* / Q000378:metabolism*; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051122:Scavenger Receptors, Class B; D015854:Up-Regulation / Q000235:genetics*
D001896:Boron Compounds; C495540:CAV1 protein, human; D018955:CD36 Antigens; C495541:Cav1 protein, mouse; D051242:Caveolin 1; D022461:Caveolins; D002788:Cholesterol Esters; D008076:Cholesterol, HDL; D007457:Iodine Radioisotopes; D008074:Lipoproteins; D008565:Membrane Proteins; D015345:Oligonucleotide Probes; D012333:RNA, Messenger; D011971:Receptors, Immunologic; D011973:Receptors, LDL; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; C454739:Scarb1 protein, mouse; D051122:Scavenger Receptors, Class B; C084200:cholesteryl 4,4-difluoro-5,7-dimethyl-4-bora-3,4-diaza-3-indacenedodecanoate; D003994:Bucladesine